Literature DB >> 20942806

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.

F A Vyth-Dreese1, J Sein, W van de Kasteele, T A M Dellemijn, C van den Bogaard, W J Nooijen, G C de Gast, J B A G Haanen, A Bex.   

Abstract

Natural killer T (NK T) cells play a central role as intermediates between innate and adaptive immune responses important to induce anti-tumour reactivity in cancer patients. In two of 14 renal cell carcinoma (RCC) patients, treated with interferon (IFN)-α, we detected significantly enhanced numbers of circulating NK T cells which were typed phenotypically and analysed for anti-tumour reactivity. These NK T cells were T cell receptor (TCR) Vα24/Vβ11(+), 6B11(+) and bound CD1d tetramers. No correlation was observed between NK T frequencies and regulatory T cells (T(regs)), which were also enhanced. NK T cells expressed CD56, CD161, CD45RO and CD69 and were predominantly CD8(+), in contrast to the circulating T cell pool that contained both CD4(+) and CD8(+) T cells, as is found in healthy individuals. It is unlikely that IFN-α triggered the high NK T frequency, as all other patients expressed low to normal NK T numbers. A parallel was observed in IFN-α-related increase in activation of NK T cells with that in conventional T and non-T cells. Normal interleukin (IL)-7, IL-12 and IL-15 plasma levels were found. In one of the patients sporadic NK T cells were detected at the tumour site. α-Galactosylceramide (αGalCer) stimulation of peripheral blood mononuclear cells or isolated NK T cell lines from both patients induced IFN-γ, but no IL-4 and no response towards autologous tumour cells or lysates. The clinical course of disease in both patients was not exceptional with regard to histological subtype and extent of metastatic disease. Therefore, despite a constitutive high peripheral frequency and in vitroαGalCer responsiveness, the NK T cells in the two RCC patients did not show anti-tumour responsiveness.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20942806      PMCID: PMC3026548          DOI: 10.1111/j.1365-2249.2010.04274.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  Natural killer T cell-mediated antitumor immune responses and their clinical applications.

Authors:  Ken-ichiro Seino; Shinichiro Motohashi; Takehiko Fujisawa; Toshinori Nakayama; Masaru Taniguchi
Journal:  Cancer Sci       Date:  2006-06-29       Impact factor: 6.716

2.  Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood.

Authors:  Yu Jing; Stefan Gravenstein; N Rao Chaganty; Nianyong Chen; Kim Herbert Lyerly; Sebastian Joyce; Yuping Deng
Journal:  Exp Gerontol       Date:  2007-02-06       Impact factor: 4.032

3.  Innate-like effector differentiation of human invariant NKT cells driven by IL-7.

Authors:  Claudia de Lalla; Nicola Festuccia; Inka Albrecht; Hyun-Dong Chang; Grazia Andolfi; Ulrike Benninghoff; Ferdinando Bombelli; Giovanna Borsellino; Alessandro Aiuti; Andreas Radbruch; Paolo Dellabona; Giulia Casorati
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 4.  Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells.

Authors:  Subramanya Hegde; Lisa Fox; Xiaohua Wang; Jenny E Gumperz
Journal:  Immunology       Date:  2010-05-11       Impact factor: 7.397

5.  Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.

Authors:  Mark A Exley; Runhua Hou; Angela Shaulov; Elena Tonti; Paolo Dellabona; Giulia Casorati; Omid Akbari; H Orhan Akman; Edward A Greenfield; Jenny E Gumperz; Jonathan E Boyson; Steven P Balk; S Brian Wilson
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

6.  A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Shinichiro Motohashi; Kaoru Nagato; Naoki Kunii; Heizaburo Yamamoto; Kazuki Yamasaki; Kohsuke Okita; Hideki Hanaoka; Naomi Shimizu; Makoto Suzuki; Ichiro Yoshino; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

7.  Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.

Authors:  Gabriel Bricard; Valerie Cesson; Estelle Devevre; Hanifa Bouzourene; Catherine Barbey; Nathalie Rufer; Jin S Im; Pedro M Alves; Olivier Martinet; Nermin Halkic; Jean-Charles Cerottini; Pedro Romero; Steven A Porcelli; H Robson Macdonald; Daniel E Speiser
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 8.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

9.  Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

Authors:  Tetsuro Uchida; Shigetoshi Horiguchi; Yuriko Tanaka; Heizaburo Yamamoto; Naoki Kunii; Shinichiro Motohashi; Masaru Taniguchi; Toshinori Nakayama; Yoshitaka Okamoto
Journal:  Cancer Immunol Immunother       Date:  2007-08-10       Impact factor: 6.968

10.  Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family.

Authors:  A C Chan; L Serwecinska; A Cochrane; L C Harrison; D I Godfrey; S P Berzins
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

View more
  1 in total

Review 1.  Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.

Authors:  Melissa Bedard; Mariolina Salio; Vincenzo Cerundolo
Journal:  Front Immunol       Date:  2017-12-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.